Title : Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management.

Pub. Date : 2010

PMID : 19900123






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The receptor tyrosine kinase (RTK) inhibitor imatinib mesylate has been approved as the first-line choice of therapy for this group of patients, while the RTK inhibitor, sunitinib malate, has been approved for the treatment of GIST after disease progression or intolerance to imatinib. Sunitinib ret proto-oncogene Homo sapiens